With everyone else gone, Knudsen was allotted the task to lead the way
Directions 1
Several generic manufacturers have already submitted applications to Health Canada and are preparing to launch their products later in 2026
Tirzepatide: What the Human Evidence Actually Shows Tirzepatides evidence base is the kind that supports an approval: large, completed, randomised Phase 3 trials with active and placebo comparators
Liraglutide is the active ingredient in both Saxenda and Victoza
multiparticulate therapeutic agent, or free base or salt or prodrug thereof) with the aid of cyclodextrins, surfactants (e.g., poloxamers (407, 338, 188), tween (80, 60, 20, 81), PEG-hydrogenated castor oil, cosolvents like N-methyl-2-Pyrrolidone or the like and preparing pulsed release formulations or compositions using any procedure described herein